Compare FTK & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTK | CTNM |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.1M | 480.5M |
| IPO Year | 1997 | 2024 |
| Metric | FTK | CTNM |
|---|---|---|
| Price | $16.88 | $12.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $19.00 |
| AVG Volume (30 Days) | 201.9K | ★ 244.9K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.06 | 0.46 |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $136,092,000.00 | N/A |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $16.38 | N/A |
| P/E Ratio | $20.71 | ★ N/A |
| Revenue Growth | ★ 214.53 | N/A |
| 52 Week Low | $6.68 | $3.35 |
| 52 Week High | $20.41 | $16.33 |
| Indicator | FTK | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 43.79 |
| Support Level | $15.89 | $11.54 |
| Resistance Level | $17.67 | $13.26 |
| Average True Range (ATR) | 0.82 | 0.60 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 69.33 | 33.13 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.